MD Anderson, Cayman Chemical, and Fannin Innovation Studio form therapeutics company
ACF Pharmaceuticals to explore the potential of novel, small molecule anti-cancer agents
MD Anderson News Release 09/15/2015
The University of Texas MD Anderson Cancer Center, Cayman Chemical and Fannin Innovation Studio have formed ACF Pharmaceuticals, LLC. The pre-clinical therapeutics company is dedicated to discovering and developing novel small molecule inhibitors for the treatment of a variety of inflammation-induced...
